
Opinion|Videos|September 8, 2023
The Evolving Landscape of Biomarker Testing in Metastatic Colorectal Cancer (mCRC)
Daniel Ahn, DO, discusses the evolution of biomarker testing in metastatic colorectal cancer, highlighting the shift from understanding only the prognostic implications of genetic alterations to recognizing their predictive role in targeted therapies, and emphasizes the potential of circulating tumor DNA for rapid diagnosis and assessing treatment response.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Understanding The Training, Credentialing Landscapes for End-of-Life Doulas
2
Withdrawal Planned for Second-Line Lurbinectedin in SCLC Indication
3
GLP-1 Receptor Agonists and Cancer: Renewed Momentum for Metabo-Oncology
4
Why CAR T-Cell Therapy Should Precede Bispecifics in Multiple Myeloma
5






























































